Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
|Abstract:||R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-q uinazolinamine hydrochloride or a pharmaceutically acceptable salt or hydratet hereof (terazosin), substantially free of the S(-)-enantiomer.|
|Inventor(s):||Kyncl; John J. (Lake Forest, IL), Horrom; Bruce W. (Waukegan, IL)|
|Assignee:||Abbott Laboratories (Abbott Park, IL)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
|Patent Number||Expiration Date|
|5,212,176||May 18, 2005|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.